Tyra Biosciences Inc TYRA

$18.56 -1.04 (-5.31%)

Valuation

Market cap
1,169,669,000
Revenue TTM
$0
Net income TTM
$-119,950,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
469,500
Avg volume
941,440
Day's range
$18.53 – $19.60
Shares out
59,677,000
Stochastic %K
1%
Beta
0.75
Analysts
Strong Sell
Price target
$47.45

Price

Company profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candid...

Show more

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Industry
Biotechnology
Sector
Healthcare
Phone
619 728 4760
Website
https://tyra.bio
Address
2656 State Street, Carlsbad, United States

Latest news

Stocktwits

Merlintrader Oct 13, 4:17 AM
Latest company news, September 14, 2026: Tyra priced an offering of 9,079,000 shares and pre-funded warrants for 9,078,529 shares at $22.03 each, for roughly $400 million in gross proceeds. Tyra Biosciences ($TYRA): Can Dabogratinib Prove Its Pediatric Growth Case? https://www.merlintrader.com/tyra-biosciences-tyra-stock-hub/
0 replies
Stockflix19 Oct 12, 1:30 PM
$AZN $MIRM $MREO $RARE $TYRA MREO 🔥
0 replies
prismmarketview Oct 12, 1:20 PM
AstraZeneca $AZN attributes its Phase 3 rare bone disease miss partly to a baseline mobility imbalance. Mereo $MREO and Ultragenyx $RARE seek an FDA path after a fracture miss. Mirum $MIRM won approval on Phase 2 data. Tyra $TYRA is testing oral dosing. https://prismmarketview.com/astrazenecas-hpp-readout-puts-trial-design-in-focus-for-rare-bone-disease-stocks/
0 replies
Social_Idiot Oct 8, 1:47 PM
$TYRA What's this about?: https://www.ftc.gov/legal-library/browse/early-termination-notices/20262300
1 replies
laaarsas Oct 8, 10:05 AM
$TYRA what results required for good price action?
0 replies
King_of_Bio Oct 7, 2:46 PM
$TYRA Just found this gem today - lovely.
1 replies
Quantumup Oct 6, 12:18 PM
Raymond James on $TYRA (Strong Buy-$50) said: Remain Strong Buy rated on TYRA shares after hosting CEO Todd Harris for a fireside chat as part of our BioPharma CEO Strategy Series (contact your RJ rep for a replay of the call). $CGON $URGN JNJ TARA IBRX ENGN Here's what Raymond James went on to say: https://x.com/Quantumup1/status/2107444841353269404?s=20
1 replies
ballerallday Sep 24, 4:14 PM
$TYRA Terrible looking technicals. Looks like much lower.
0 replies